Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 21

Results For "type-2"

227 News Found

UAE authorises Sputnik Light vaccine as universal booster
News | November 30, 2021

UAE authorises Sputnik Light vaccine as universal booster

Booster dose is available to all residents aged 18+ and can be applied six months after the second dose of any other vaccine administered in UAE


Sputnik Light in India by December: RDIF
News | November 25, 2021

Sputnik Light in India by December: RDIF

One-shot Sputnik Light is a highly effective vaccine when used both on standalone basis and applied as a booster


Novo Nordisk to acquire Dicerna Pharmaceuticals for US $ 3.3 bn
Biotech | November 20, 2021

Novo Nordisk to acquire Dicerna Pharmaceuticals for US $ 3.3 bn

Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease


Biocon Biologics and Viatris announce US launch of Semglee
News | November 17, 2021

Biocon Biologics and Viatris announce US launch of Semglee

Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes


Pre-diabetes is a much more serious issue in India: Fitterfly
News | November 16, 2021

Pre-diabetes is a much more serious issue in India: Fitterfly

Two out of three people under the age of 40 are at risk of prediabetes


Alarming rise in diabetes amongst children and adolescents in India
News | November 14, 2021

Alarming rise in diabetes amongst children and adolescents in India

The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue


Solve.Care and AliveCor partner to connect KardiaMobile users with physicians
Digitisation | October 29, 2021

Solve.Care and AliveCor partner to connect KardiaMobile users with physicians

The collaboration provides KardiaMobile users quick access to doctors worldwide for consultations about their ECG readings


Glenmark launches novel fixed-dose combination for diabetes
Drug Approval | October 26, 2021

Glenmark launches novel fixed-dose combination for diabetes

It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination


U.S. FDA expands approval of Dupixent to include children aged 6 to 11 years
Drug Approval | October 22, 2021

U.S. FDA expands approval of Dupixent to include children aged 6 to 11 years

Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option


Sputnik Light has 70 % efficacy against infection with Delta: Gamaleya analysis
Biotech | October 14, 2021

Sputnik Light has 70 % efficacy against infection with Delta: Gamaleya analysis

Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations